Your browser doesn't support javascript.
loading
Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
Baranzini, Sergio E; Madireddy, Lohith R; Cromer, Anne; D'Antonio, Mauro; Lehr, Lorenz; Beelke, Manolo; Farmer, Pierre; Battaglini, Marco; Caillier, Stacy J; Stromillo, Maria L; De Stefano, Nicola; Monnet, Emmanuel; Cree, Bruce A C.
Afiliación
  • Baranzini SE; Department of Neurology, University of California, San Francisco (UCSF), San Francisco, USA/ Equal contribution sebaran@cgl.ucsf.edu.
  • Madireddy LR; Department of Neurology, University of California, San Francisco (UCSF), San Francisco, USA/ Equal contribution.
  • Cromer A; Merck Serono S.A. - Geneva, Switzerland/During the completion of this study, Merck Serono closed its Geneva operations. These authors are no longer with the company.
  • D'Antonio M; Merck Serono RBM S.p.A- Colleretto Giacosa, Turin, Italy.
  • Lehr L; Merck Serono S.A. - Geneva, Switzerland/During the completion of this study, Merck Serono closed its Geneva operations. These authors are no longer with the company.
  • Beelke M; Merck Serono S.A. - Geneva, Switzerland/During the completion of this study, Merck Serono closed its Geneva operations. These authors are no longer with the company.
  • Farmer P; Merck Serono S.A. - Geneva, Switzerland/During the completion of this study, Merck Serono closed its Geneva operations. These authors are no longer with the company.
  • Battaglini M; University of Siena, Siena, Italy.
  • Caillier SJ; Department of Neurology, University of California, San Francisco (UCSF), San Francisco, USA/ Equal contribution.
  • Stromillo ML; Department of Neurology, University of California, San Francisco (UCSF), San Francisco, USA/ Equal contributionDepartment of Neurology, University of California, San Francisco (UCSF), San Francisco, USA/ Equal contributionMerck Serono S.A. - Geneva, Switzerland/During the completion of this study, M
  • De Stefano N; Department of Neurology, University of California, San Francisco (UCSF), San Francisco, USA/ Equal contributionDepartment of Neurology, University of California, San Francisco (UCSF), San Francisco, USA/ Equal contributionMerck Serono S.A. - Geneva, Switzerland/During the completion of this study, M
  • Monnet E; Merck Serono S.A. - Geneva, Switzerland/During the completion of this study, Merck Serono closed its Geneva operations. These authors are no longer with the company.
  • Cree BA; Department of Neurology, University of California, San Francisco (UCSF), San Francisco, USA/ Equal contribution.
Mult Scler ; 21(7): 894-904, 2015 Jun.
Article en En | MEDLINE | ID: mdl-25392319
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores / Interferón beta / Esclerosis Múltiple Recurrente-Remitente / Factores Inmunológicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores / Interferón beta / Esclerosis Múltiple Recurrente-Remitente / Factores Inmunológicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2015 Tipo del documento: Article